Which has the lower trailing P/E, ALNY or DXCM?

DXCM has the lower trailing P/E: ALNY trades at 40.05 and DXCM at 35.90. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or DXCM?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus DXCM at 18.03%.

Is ALNY or DXCM more profitable?

DXCM runs the higher net margin — ALNY at 16.82% versus DXCM at 20.12%.

How have ALNY and DXCM total returns compared?

Over the past 10 years, ALNY delivered 12.84% and DXCM delivered 14.81% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs DexCom, Inc. (DXCM)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and DexCom, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 29, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$31.73B

$237.10HealthcareAt close: Aug 28, 2026, 4:00 PM ET

DXCM

DexCom, Inc.

$34.27B

$90.82HealthcareAt close: Aug 28, 2026, 4:00 PM ET

Total return — ALNY vs DXCM

growth of $100 · dividends reinvested · last 10y

ALNY +231.3% (+12.7%/yr)DXCM +300.8% (+14.9%/yr)DXCM compounded faster over this window

ALNY DXCM

ALNY vs DXCM: by the numbers

•DXCM is the larger company ($34.27B vs $31.73B market cap).
•DXCM trades at the lower trailing earnings multiple (35.90 vs 40.05 P/E), one valuation lens rather than an overall verdict.
•DXCM converts more revenue to profit (20.12% vs 16.82% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 18.03% CAGR).

Metrics side by side

Valuation

Metric	ALNY	DXCM
P/E ratio	40.05	35.90
Forward P/E	36.43	34.05
P/S ratio	6.82	7.16
P/B ratio	24.21	13.57
EV / EBITDA	30.68	25.57
FCF yield	1.66%	3.95%

Profitability

Metric	ALNY	DXCM
Gross margin	79.72%	62.47%
Operating margin	20.81%	22.92%
Net margin	16.82%	20.12%
ROE	59.67%	38.14%
ROIC	24.71%	21.71%

Growth (annualized)

Metric	ALNY	DXCM
Revenue CAGR (5Y)	47.53%	18.03%
EPS CAGR (5Y)	N/A	10.31%
FCF CAGR (5Y)	N/A	69.49%
Total return CAGR (5Y)	3.06%	-6.94%

Frequently asked

Which has the lower trailing P/E, ALNY or DXCM?: DXCM has the lower trailing P/E: ALNY trades at 40.05 and DXCM at 35.90. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or DXCM?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus DXCM at 18.03%.
Is ALNY or DXCM more profitable?: DXCM runs the higher net margin — ALNY at 16.82% versus DXCM at 20.12%.
How have ALNY and DXCM total returns compared?: Over the past 10 years, ALNY delivered 12.84% and DXCM delivered 14.81% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full DXCM analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio DexCom P/E ratio Alnylam Pharmaceuticals ROE DexCom ROE Alnylam Pharmaceuticals operating margin DexCom operating margin Alnylam Pharmaceuticals revenue growth DexCom revenue growth Alnylam Pharmaceuticals free cash flow DexCom free cash flow

Alnylam Pharmaceuticals & DexCom appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 29, 2026.